SELLAS Announces Positive Phase 2 Preliminary Data of SLS009

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

China , Angelos Stergiou , Bruce Mackle , Joshua Zeidner , Life Sciences Group Inc , Drug Administration , Leukemia Research , Company Filed Ip Protection , World Health Organization , Lifesci Advisors , Nasdaq , Division Of Hematology , Genfleet Therapeutics Shanghai Inc , Memorial Sloan Kettering Cancer Center , Clinical Cancer Research Commercial Integration , Positive Phase , Response Rate , Optimal Dose , Company Filed , Highly Prevalent Gene Mutation , Myeloid Malignancies , Solid Tumors With Significant Market Potential , Overall Response Rate , All Patients Alive , Further Support , Potential Accelerated Approval Pathway , Defined Patient Population , Strong Anti Leukemic Activity , Enrollment Ongoing , Expansion Cohort , Updates Expected , Sciences Group , Associate Professor , Associate Chief , Chief Executive Officer , Hematologic Malignancies , Acute Myeloid Leukemia , Myelodysplastic Syndrome , Myeloproliferative Neoplasms , Chronic Myelomonocytic Leukemia , Solid Cancers , Colorectal Cancer , High Microsatellite Instability , Genfleet Therapeutics , Annual Report , Sci Advisors ,